Welcome to our dedicated page for TenX Keane Acquisition news (Ticker: TENKU), a resource for investors and traders seeking the latest updates and insights on TenX Keane Acquisition stock.
The news feed for TENKU focuses on the public disclosures and transaction milestones of TenX Keane Acquisition, a blank check company formed to complete a business combination, and its merger with the oncology subsidiary of Citius Pharmaceuticals, Inc. News releases describe TenX Keane Acquisition’s initial public offering on Nasdaq, its trust account structure, and multiple extensions of the deadline to complete an initial business combination.
Subsequent coverage highlights the definitive agreement between TenX Keane Acquisition and the Citius oncology subsidiary to form Citius Oncology, Inc., a publicly listed company intended to trade under the symbol CTOR. Articles report that TenX shareholders approved the business combination at an extraordinary general meeting and outline how the transaction is structured, including the conversion of the subsidiary’s shares into common stock of Citius Oncology.
Because the target of TenX Keane Acquisition’s merger is an oncology-focused pharmaceutical company, the TENKU news stream also includes context from Citius Pharmaceuticals, Inc. regarding its oncology subsidiary and product candidate LYMPHIR, as described in joint press releases. These items explain how the merger is expected to support the development and commercialization of targeted oncology therapies through the Citius Oncology platform.
Investors and observers who follow TENKU-related news can use this page to review historical announcements about the SPAC’s formation, its financing and extension arrangements, shareholder votes, and the evolution toward Citius Oncology, Inc. For current operational updates, filings and press releases issued under the Citius Oncology, Inc. name provide more detailed information on the oncology business that emerged from the TenX Keane Acquisition transaction.
TenX Keane Acquisition (Nasdaq: TENKU) faced a trading halt on August 7, 2024, due to additional information requested by Nasdaq following unusual trading activity. The company is working with Nasdaq to lift the halt. Meanwhile, TenX shareholders approved the merger with Citius Oncology on August 2, 2024. The post-merger entity is expected to trade as Citius Oncology, Inc. (CTOR) on Nasdaq.
In a related development, Citius Pharmaceuticals (Nasdaq: CTXR) announced FDA approval for LYMPHIR™, a treatment for relapsed or refractory cutaneous T-cell lymphoma. TenX and Citius Pharma are progressing towards closing the business combination in the near future.
TenX Keane Acquisition shareholders have approved the merger with Citius Pharmaceuticals' oncology subsidiary to form Citius Oncology, Inc. The vote took place at an extraordinary general meeting on August 2, 2024. The newly combined company is expected to trade on Nasdaq under the Citius Oncology name. This merger aims to support the commercialization of LYMPHIR, pending approval, and explore additional oncology assets. The transaction is anticipated to provide Citius Oncology with improved access to public equity markets. Subject to closing conditions, the merger is expected to be completed in the coming weeks. This strategic move positions Citius Oncology to advance its oncology pipeline and potentially strengthen its market presence in the biopharmaceutical sector.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
TenX Keane Acquisition (NASDAQ:TENKU) announced the closing of its initial public offering (IPO) of 6,600,000 units at an offering price of $10.00 per unit, generating $66,000,000 in gross proceeds. The IPO included a partial exercise of the underwriter's over-allotment option for 600,000 units. Each unit consists of one ordinary share and one right, with rights entitling holders to receive two-tenths of one share upon the initial business combination. The units began trading on NASDAQ under the symbol TENKU on October 14, 2022.